Brandon has over a decade of experience working in the pharmaceutical, CRO, and medical communications industries. As the biotechnology portfolio lead, he provides medical strategy and overall account direction for a variety of pharmaceutical companies with needs spanning from preclinical development to post-market and product lifecycle management.
Brandon obtained his PhD at the University of Chicago in molecular metabolism and performed postdoctoral work in the cardiometabolic department of MedImmune/AstraZeneca where he investigated novel combinatorial peptide-based therapies for Type 2 Diabetes and NASH which have subsequently moved into clinical development.